hydroxychloroquine

JYD exerts therapeutic effects in SS model mice, likely by inhibiting the NF-κB signaling pathway, enhancing AQP5 protein expression, and thereby attenuating the production of proinflammatory cytokines.

Hydroxychloroquine (HCQ) is conditionally recommended for established autoimmune diseases or specific inflammatory placental pathologies...Maternal inflammation is a primary trigger for disturbed placentation and fetal loss. Improving outcomes for women with RPL requires a proactive, evidence-based approach that specifically targets the immunological bystander reaction pathway rather than relying on routine clotting tests.

P2, N=100, Not yet recruiting, Kunming Pharmaceuticals, Inc.

P4, N=43, Terminated, Guy's and St Thomas' NHS Foundation Trust | Active, not recruiting --> Terminated; Recruitment was terminated early by the funder due to study sites' inability to recruit sufficient number of participants.

P2/3, N=189, Completed, Celltrion Inc. | Active, not recruiting --> Completed

We present a 62-year-old female patient with severe clinical presentation of AD, characterized by diffuse severe alopecia and pronounced symmetrical livid edema of the upper and lower eyelid, and positive anti-melanoma differentiation-associated gene 5 (anti-MDA-5) antibodies, who was successfully treated with concurrent therapy with hydroxychloroquine, methylprednisolone, and methotrexate as well as topical corticosteroids...Furthermore, we recommend vigilance in the key differential diagnosis of cutaneous lupus erythematosus because they can both present with similar clinical and histopathological features. The remission correlated with the complete absence of anti-MDA-5 antibodies.

Among patients with actively treated RA, eGFRcys is consistently lower than eGFRcr. Neither eGFRcys nor eGFRcr demonstrated a change following RA treatments, despite reductions in the disease activity biomarker TNF-RI. Further studies incorporating directly measured GFR are warranted.

P3, N=70000, Recruiting, University of Oxford | Trial completion date: Jun 2036 --> Sep 2038 | Trial primary completion date: Jun 2026 --> Sep 2028

P1/2, N=93, Recruiting, VA Office of Research and Development | Not yet recruiting --> Recruiting

P2, N=25, Terminated, University Hospital, Rouen | Completed --> Terminated; Difficulty in enrolling new patients

P2, N=20, Terminated, Cancer Trials Ireland | Trial completion date: Jun 2026 --> Mar 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Sep 2025 --> Mar 2026; Study terminated due to futility

Treatment with immunosuppressants such as corticosteroids, hydroxychloroquine, and azathioprine resulted in symptomatic improvement. However, the disease course was complicated by constrictive pericarditis requiring pericardiectomy and later inflammatory arthritis requiring escalation of immunosuppression. This case highlights the importance of considering autoimmune etiologies in patients with unexplained multisystem effusions and elevated tumor markers, thereby avoiding misdiagnosis and unnecessary oncological interventions.